Regeneron Earnings: Is Now the Time to Buy?

Regeneron’s Eylea sales slowed down slightly during the first quarter, although the company beat estimates on both the top and bottom lines.

May 12, 2014 at 3:25PM

Regeneron (NASDAQ:REGN) reported its first-quarter earnings on May 8, topping analyst expectations on both the top and bottom lines. Regeneron's non-GAAP diluted earnings rose 27% year over year to $2.26 per share, or $263 million, topping the Thomson Reuters consensus estimate of $2.20 per share.

Regeneron's revenue rose 42% to $626 million, topping the consensus estimate of $609 million. However, U.S. sales of the eye treatment Eylea, the company's main source of revenue, rose 14% to $359 million, missing analyst estimates of $404 million.

REGN Chart

Regeneron attributed the slowdown in Eylea sales to a decrease in distributor inventory and a harsh winter in the U.S., which kept more patients at home. Regeneron's partner Bayer (NASDAQOTH:BAYRY) markets Eylea outside the United States, where it reported sales of $218 million -- a 252% jump from the prior year quarter. Regeneron received $61 million from its share of Eylea profits outside the United States during the quarter. Regeneron finished the quarter with $1.18 billion in cash -- a 9% increase from the prior year quarter.

Overall, Regeneron delivered robust earnings and revenue growth, but the stock fell nearly 2% after earnings. However, let's take a look at why Regeneron is still a solid investment at current prices.

The slump in Eylea sales will only be temporary
Investors shouldn't be concerned about weaker-than-expected sales of Eylea. Regeneron reaffirmed its forecast for $1.7 billion in $1.8 billion in U.S. Eylea sales by the end of the year -- which would signify a healthy 21% to 28% increase from 2013 sales. Last year, Eylea generated $1.88 billion in sales worldwide. Analysts at UBS believe sales could go much higher, hitting peak sales of $3.7 billion by 2020.

However, Eylea needs to be approved for several additional indications before it can hit those peak estimates. Eylea lags behind its primary competitor, Novartis (NYSE:NVS) and Roche's (NASDAQOTH:RHHBY) Lucentis, in terms of total approved indications:




Wet Age-related macular degeneration (AMD)

approved (U.S. and Europe)

approved (U.S. and Europe)

Diabetic macular edema (DME)

Phase 3, BLA submitted

approved (U.S. and Europe)

Macular edema following central retinal vein occlusion (CRVO)

approved (U.S. and Europe)

approved (U.S. and Europe)

Macular Edema following branch retinal vein occlusion (BRVO)

Phase 3, BLA submitted

approved (U.S. and Europe)

Choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV)

Phase 3

approved (Europe)

Source: Company websites, press releases.

Of these indications, the most important one is diabetic macular edema, or DME. DME affects approximately 8% of diabetics within the first five years of the disease, with 42% eventually developing the condition later in their lives. The FDA will reach a decision regarding the supplemental BLA (biologics license application) for Eylea's DME indication on August 18, which could be a positive catalyst for the stock.

Investors should also note that Roche's Avastin has been gaining acceptance as an off-label treatment for both Wet AMD, DME, and other eye conditions. The reason is the price -- Avastin can cost as little as $50 per injection, much less than Lucentis and Eylea, which both cost up to $2,000 per dose.

A trio of potential blockbusters
Looking beyond Eylea, however, Regeneron is also developing a trio of potential blockbusters in its pipeline with Sanofi (NYSE:SNY). These three fully human monoclonal antibodies -- alirocumab, sarilumab, and dupilumab, are the keys to beefing up Regeneron's long-term portfolio:


Potential Indication


Peak Sales Estimate


lower "bad" LDL cholesterol

Phase 3

$3.5 billion (Goldman Sachs)


rheumatoid arthritis

Phase 3

$3.1 billion(SG Cross)


allergic diseases

Phase 2b

$2.8 billion (Leerink Swann)

Sources: Company and industry websites.

Alirocumab is a similar treatment to Amgen's AMG 145 (evolocumab) and Pfizer's RN-316. All three treatments target PCSK9, an enzyme which binds to the liver's LDL receptors and degrades their ability to lower LDL cholesterol levels. AMG-145 and RN-316 are currently in phase 3 trials as well.

Meanwhile, Sarilumab targets a very lucrative market -- rheumatoid arthritis treatments, such as Johnson & Johnson and Merck's Remicade, Amgen's Enbrel, and AbbVie's Humira are among the top-selling drugs in the world.

The Foolish takeaway
In conclusion, investors shouldn't fret about the temporary lull in Eylea sales. Eylea still has lots of room to grow, and an additional approval for DME could help keep the pressure on Lucentis. Long-term investors should focus on the development of Regeneron and Sanofi's three potential blockbusters -- which could grow into exciting new pillars of growth for both companies.

Six stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently, one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his six carefully chosen picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

A Financial Plan on an Index Card

Keeping it simple.

Aug 7, 2015 at 11:26AM

Two years ago, University of Chicago professor Harold Pollack wrote his entire financial plan on an index card.

It blew up. People loved the idea. Financial advice is often intentionally complicated. Obscurity lets advisors charge higher fees. But the most important parts are painfully simple. Here's how Pollack put it:

The card came out of chat I had regarding what I view as the financial industry's basic dilemma: The best investment advice fits on an index card. A commenter asked for the actual index card. Although I was originally speaking in metaphor, I grabbed a pen and one of my daughter's note cards, scribbled this out in maybe three minutes, snapped a picture with my iPhone, and the rest was history.

More advisors and investors caught onto the idea and started writing their own financial plans on a single index card.

I love the exercise, because it makes you think about what's important and forces you to be succinct.

So, here's my index-card financial plan:


Everything else is details. 

Something big just happened

I don't know about you, but I always pay attention when one of the best growth investors in the world gives me a stock tip. Motley Fool co-founder David Gardner (whose growth-stock newsletter was rated #1 in the world by The Wall Street Journal)* and his brother, Motley Fool CEO Tom Gardner, just revealed two brand new stock recommendations moments ago. Together, they've tripled the stock market's return over 12+ years. And while timing isn't everything, the history of Tom and David's stock picks shows that it pays to get in early on their ideas.

Click here to be among the first people to hear about David and Tom's newest stock recommendations.

*"Look Who's on Top Now" appeared in The Wall Street Journal which references Hulbert's rankings of the best performing stock picking newsletters over a 5-year period from 2008-2013.

Compare Brokers